Mucinex to tap into robust nighttime market

PARSIPPANY, N.J. — Reckitt Benckiser this season extended its line of popular Mucinex Fast-Max to include a product for nighttime cold and flu relief in both liquid and tablet form.

According to the company, nighttime relief is a $600 million market in the United States, and Mucinex Fast-Max is differentiated from its competitors because it contains an active ingredient for nasal decongestion.

Reckitt Benckiser’s Mucinex Fast-Max tablets reached $80.5 million in sales on a 307.7% lift. And sales of Mucinex Fast-Max liquid formulations were up 29.7% to $94.3 million for the 52 weeks ended Dec. 1 across U.S. total multi-outlets, according to IRI.